메뉴 건너뛰기




Volumn 11, Issue 3, 2010, Pages 291-293

Tyrosine kinase inhibitors and acute pancreatitis

Author keywords

4 amino 5 (4 methylphenyl) 7 (tert butyl)pyrazolo (3,4 d)pyrimidine; Amylases; Clinical trials; Controlled clinical trial; Drug toxicity; Lipase; Pancreatitis

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; CD135 ANTIGEN; IMATINIB; NILOTINIB; PANCREAS ENZYME; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

EID: 77953665094     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (39)

References (24)
  • 2
    • 77954476036 scopus 로고    scopus 로고
    • Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid Cancer: The M. D. Anderson experience
    • Apr 14. [PMID 20392874]
    • Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid Cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 2010; Apr 14. [PMID 20392874]
    • (2010) J Clin Endocrinol Metab
    • Cabanillas, M.E.1    Waguespack, S.G.2    Bronstein, Y.3    Williams, M.D.4    Feng, L.5    Hernandez, M.6
  • 3
    • 0034032012 scopus 로고    scopus 로고
    • BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia
    • [PMID 10766197]
    • Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 2000;60:2049-55. [PMID 10766197]
    • (2000) Cancer Res , vol.60 , pp. 2049-2055
    • Deininger, M.W.1    Vieira, S.2    Mendiola, R.3    Schultheis, B.4    Goldman, J.M.5    Melo, J.V.6
  • 4
    • 71849103177 scopus 로고    scopus 로고
    • Advances in the biology and therapy of patients with chronic myeloid leukaemia
    • [PMID 19959090]
    • Jabbour E, Fava C, Kantarjian H. Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22:395-407. [PMID 19959090]
    • (2009) Best Pract Res Clin Haematol , vol.22 , pp. 395-407
    • Jabbour, E.1    Fava, C.2    Kantarjian, H.3
  • 5
    • 20044382799 scopus 로고    scopus 로고
    • Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
    • [PMID 15613696]
    • Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-72. [PMID 15613696]
    • (2005) J Clin Oncol , vol.23 , pp. 965-972
    • Strumberg, D.1    Richly, H.2    Hilger, R.A.3    Schleucher, N.4    Korfee, S.5    Tewes, M.6
  • 6
    • 33745086350 scopus 로고    scopus 로고
    • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
    • [PMID 16775235]
    • Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542-51. [PMID 16775235]
    • (2006) N Engl J Med , vol.354 , pp. 2542-2551
    • Kantarjian, H.1    Giles, F.2    Wunderle, L.3    Bhalla, K.4    O'Brien, S.5    Wassmann, B.6
  • 7
    • 37249072373 scopus 로고    scopus 로고
    • A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
    • [PMID 17505827]
    • Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008; 61:515-24. [PMID 17505827]
    • (2008) Cancer Chemother Pharmacol , vol.61 , pp. 515-524
    • Britten, C.D.1    Kabbinavar, F.2    Hecht, J.R.3    Bello, C.L.4    Li, J.5    Baum, C.6    Slamon, D.7
  • 8
    • 36249017922 scopus 로고    scopus 로고
    • Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma
    • [PMID 17951335]
    • Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37:755-62. [PMID 17951335]
    • (2007) Jpn J Clin Oncol , vol.37 , pp. 755-762
    • Akaza, H.1    Tsukamoto, T.2    Murai, M.3    Nakajima, K.4    Naito, S.5
  • 9
    • 36949033865 scopus 로고    scopus 로고
    • Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
    • [PMID 17953709]
    • Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99:159-65. [PMID 17953709]
    • (2008) Cancer Sci , vol.99 , pp. 159-165
    • Furuse, J.1    Ishii, H.2    Nakachi, K.3    Suzuki, E.4    Shimizu, S.5    Nakajima, K.6
  • 10
    • 41349083969 scopus 로고    scopus 로고
    • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
    • [PMID 18048643]
    • le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111:1834-9. [PMID 18048643]
    • (2008) Blood , vol.111 , pp. 1834-1839
    • le Coutre, P.1    Ottmann, O.G.2    Giles, F.3    Kim, D.W.4    Cortes, J.5    Gattermann, N.6
  • 11
    • 53049083618 scopus 로고    scopus 로고
    • Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib
    • [PMID 18765523]
    • Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008; 14:5325-31. [PMID 18765523]
    • (2008) Clin Cancer Res , vol.14 , pp. 5325-5331
    • Hazarika, M.1    Jiang, X.2    Liu, Q.3    Lee, S.L.4    Ramchandani, R.5    Garnett, C.6
  • 12
    • 67651095716 scopus 로고    scopus 로고
    • Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis
    • [PMID 19247201]
    • Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43:489-95. [PMID 19247201]
    • (2009) J Clin Gastroenterol , vol.43 , pp. 489-495
    • Wörns, M.A.1    Weinmann, A.2    Pfingst, K.3    Schulte-Sasse, C.4    Messow, C.M.5    Schulze-Bergkamen, H.6
  • 13
    • 67349171532 scopus 로고    scopus 로고
    • Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: A retrospective analysis
    • [PMID 19371877]
    • Medioni J, Choueiri TK, Zinzindohoué F, Cho D, Fournier L, Oudard S. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. J Urol 2009; 181:2470-5. [PMID 19371877]
    • (2009) J Urol , vol.181 , pp. 2470-2475
    • Medioni, J.1    Choueiri, T.K.2    Zinzindohoué, F.3    Cho, D.4    Fournier, L.5    Oudard, S.6
  • 14
    • 67749145142 scopus 로고    scopus 로고
    • A Phase I/II study of nilotinib in Japanese patients with imatinibresistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL
    • [PMID 19449194]
    • Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, et al. A Phase I/II study of nilotinib in Japanese patients with imatinibresistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. Int J Hematol 2009; 89:679-88. [PMID 19449194]
    • (2009) Int J Hematol , vol.89 , pp. 679-688
    • Tojo, A.1    Usuki, K.2    Urabe, A.3    Maeda, Y.4    Kobayashi, Y.5    Jinnai, I.6
  • 15
    • 68649087402 scopus 로고    scopus 로고
    • Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: A singleand multiple-dose, open-label pharmacokinetic study in Chinese patients
    • [PMID 19695406]
    • Zhou L, Meng F, Yin O, Wang J, Wang Y, Wei Y, et al. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a singleand multiple-dose, open-label pharmacokinetic study in Chinese patients. Clin Ther 2009; 31:1568-75. [PMID 19695406]
    • (2009) Clin Ther , vol.31 , pp. 1568-1575
    • Zhou, L.1    Meng, F.2    Yin, O.3    Wang, J.4    Wang, Y.5    Wei, Y.6
  • 16
    • 73949145209 scopus 로고    scopus 로고
    • Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
    • [PMID 19822896]
    • Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114:4933-8. [PMID 19822896]
    • (2009) Blood , vol.114 , pp. 4933-4938
    • Rosti, G.1    Palandri, F.2    Castagnetti, F.3    Breccia, M.4    Levato, L.5    Gugliotta, G.6
  • 18
    • 34247579261 scopus 로고    scopus 로고
    • Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
    • National Cancer Institute
    • National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Cancer Therapy Evaluation Program (CTEP), 2006.
    • (2006) Cancer Therapy Evaluation Program (CTEP)
  • 20
    • 34548448493 scopus 로고    scopus 로고
    • Acute pancreatitis associated with sorafenib
    • [PMID 17902294]
    • Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J 2007; 100:909-11. [PMID 17902294]
    • (2007) South Med J , vol.100 , pp. 909-911
    • Li, M.1    Srinivas, S.2
  • 21
    • 34047233913 scopus 로고    scopus 로고
    • Sorafenib-induced pancreatitis
    • [PMID 17418082]
    • Amar S, Wu KJ, Tan WW. Sorafenib-induced pancreatitis. Mayo Clin Proc 2007; 82:521. [PMID 17418082]
    • (2007) Mayo Clin Proc , vol.82 , pp. 521
    • Amar, S.1    Wu, K.J.2    Tan, W.W.3
  • 22
    • 77953660642 scopus 로고    scopus 로고
    • Sorafenib-induced acute pancreatitis. JOP
    • Saadati H, Saif MW. Sorafenib-induced acute pancreatitis. JOP. J Pancreas (Online) 2010; 11:283-4.
    • (2010) J Pancreas (Online) , vol.11 , pp. 283-284
    • Saadati, H.1    Saif, M.W.2
  • 23
    • 33746253902 scopus 로고    scopus 로고
    • Vascular endothelial growth factor increases in serum and protects against the organ injuries in severe acute pancreatitis
    • [PMID 16488441]
    • Ueda T, Takeyama Y, Yasuda T, Matsumura N, Sawa H, Nakajima T, Kuroda Y. Vascular endothelial growth factor increases in serum and protects against the organ injuries in severe acute pancreatitis. J Surg Res 2006; 134:223-30. [PMID 16488441]
    • (2006) J Surg Res , vol.134 , pp. 223-230
    • Ueda, T.1    Takeyama, Y.2    Yasuda, T.3    Matsumura, N.4    Sawa, H.5    Nakajima, T.6    Kuroda, Y.7
  • 24
    • 0024360854 scopus 로고
    • Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms
    • [PMID 2745556]
    • Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Griffin GL, Senior RM, Deuel TF. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. J Cell Biol 1989; 109:429-40. [PMID 2745556]
    • (1989) J Cell Biol , vol.109 , pp. 429-440
    • Pierce, G.F.1    Mustoe, T.A.2    Lingelbach, J.3    Masakowski, V.R.4    Griffin, G.L.5    Senior, R.M.6    Deuel, T.F.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.